Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck wins Japanese approval for colorectal cancer drug
On the basis of the submitted data, the label allows the use of Erbitux plus irinotecan in second- and further lines of metastatic colorectal cancer. Erbitux was approved
On the basis of the submitted data, the label allows the use of Erbitux plus irinotecan in second- and further lines of metastatic colorectal cancer. Erbitux was approved
Bravo is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for
According to the company, the Merlin@home transmitter’s wireless technology gives patients the additional comfort of having devices automatically checked. Since the transmitter initiates the scheduled follow-up and uses
Pursuant to the closing of this financing round, Frazier’s general partner, Patrick Heron, has joined the Collegium board of directors. Previous investors Boston Millennia Partners and Westfield Capital
The company is following advice provided by the drug safety monitoring board and the steering committee, which have been continuously monitoring the trial’s progress. On the basis of
The investors have agreed to purchase the shares at a purchase price of $17.85 per share resulting in gross proceeds of approximately $25.9 million to Pharmasset, before deducting
The family of six complementary patents covers methods of genetic analysis used to detect markers for multifactorial traits. According to the company, these methods range from identification of
The LabChip GX represents a low price entry system targeted at genomics applications, while the GXII combines both genomics and protein research applications. The LabChip GX series of
Under the terms of the collaboration, Power3 in partnership with the Princess Haya Biotechnology Center and the Jordan University of Science and Technology will start a clinical validation
The European Commission’s approval allows Jerini to market Firazyr in the EU’s 27 member states, making it the first product to be approved in all EU countries for